Autonomix Medical, a leading medical device company, saw a significant increase in its shares, rising by 13% to reach $4.30. This surge followed the completion of the site initiation for its groundbreaking proof-of-concept human clinical study. The study aims to evaluate the efficacy of transvascular radiofrequency ablation in alleviating pancreatic cancer pain.
With the site initiation phase now concluded, Autonomix Medical is actively identifying and training principal investigators who will be responsible for overseeing the study. The company remains on track to commence patient enrollment during this quarter.
The primary objective of this clinical study is to successfully ablate somatic nerves that are directly linked to pancreatic cancer pain. By utilizing a transvascular approach to reach the affected nerves, the study aims to mitigate the pain experienced by patients. A total of twenty subjects will be enrolled in this study, which will be conducted at a single clinical trial site. The enrollment process is expected to be completed before the end of 2024.
Looking ahead, Autonomix Medical anticipates obtaining clearance from the Food and Drug Administration (FDA) by 2027. This clearance is crucial for the future development and application of their groundbreaking treatment.
